type 1 diabetes program (Veralox Therapeutics)

N/A

Report date: 2025/03/20 10:07:58
NME

Base Information

Drug Nametype 1 diabetes program (Veralox Therapeutics)
Drug Alias Name12-lipoxygenase inhibitor (Veralox Therapeutics)12-HETE inhibitor (Veralox Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action12-lipoxygenase inhibitors
Targets12-lipoxygenase
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVeralox Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVeralox Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A